Trial data comparison: difference between revisions
Diff·revision 19 → 20·11:03, 1 Mar 2025
Difference between revision 19 and revision 20 of Trial data comparison. 7 lines changed; the page grew by 439 bytes.
| Revision 19 — 03:15, 25 Feb 2025 MTC_Marisol (talk) rm citation to a supplier's own page 2,396 bytes ±0 | Revision 20 — 11:03, 1 Mar 2025 GlossaryGleb (talk) restructure 2,835 bytes +439 | ||
|---|---|---|---|
| 20 | Filter by compound, trial programme or endpoint type. The bar is drawn to the magnitude of the primary result and is scaled within its endpoint type only. | 20 | Filter by compound, trial programme or endpoint type. The bar is drawn to the magnitude of the primary result and is scaled within its endpoint type only. |
| 21 | 21 | ||
| + | 22 | == Why the estimand matters == | |
| + | 23 | {{main|Intention-to-treat analysis}} | |
| + | 24 | ||
| + | 25 | A weight-change endpoint can be summarised in at least two defensible ways, and the ICH E9(R1) addendum names them.{{r|ich9r1}} | |
| + | 26 | ||
| + | 27 | The '''treatment-policy estimand''' asks what happened to everyone randomised, including those who stopped the drug and those who started another one. It answers "what does prescribing this achieve", and it is the more conservative figure. | |
| + | 28 | ||
| 22 | == References == | 29 | == References == |
| 23 | {{reflist}} | 30 | {{reflist}} |